Neutralizing Antibody Induction by Centralized Genes

集中基因诱导中和抗体

基本信息

  • 批准号:
    7756630
  • 负责人:
  • 金额:
    $ 45.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-02-01 至 2010-01-31
  • 项目状态:
    已结题

项目摘要

Centralized HIV-1 immunogen approach is an important strategy to explore for preclinical testing to overcome HIV- diversity. For induction of neutralizing antibodies, centralized genes should capture the conserved Env regions that are important for virus infectivity. We have recently shown in initial proof of concept studies for use of consensus Envs for immunogen design, that year 1999 CON6 gp120 and gp140 Env proteins expressed wildtype Env neutralizing epitopes, and were able to induce antibodies that neutralized about 30% of wild-type HIV-1 primary isolates. The second proof of concept milestone needed for a firm rationale for the work proposed in Project 2 has also been achieved within the last year?that of demonstration of iterative improvement of consensus gene induction of neutralizing antibodies, with year 2001 anti-CON-S gp140CFI antibodies shown to neutralize the same spectrum of B isolates as CONG gp140, and, in addition, shown to neutralize a significant subset of non-B HIV-1 primary isolates. Project 2 will synergize with Projects 1, 3 and 4 and Cores B and C by exploring ways to further enhance the immunogenicity of centralized HIV-1 genes and proteins for their ability to induce more broadly reactive neutralizing anti-HIV-1 antibodies. Specific Aim 1. To determine the immunogenicity of newer group M consensus and subtype consensus Envs compared to Year 2001 group M consensus Env, CON-S. Specific Aim 2. To enhance the immunogenicity of Year 2001 CON-S Env for induction of neutralizing antibodies. Specific Aim 3. To determine the antigenicity and immunogenicity of newly designed centralized Envs from Project 1 and Core B.
集中的HIV-1免疫原方法是临床前检测的重要探索策略

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elizabeth Anne Ramsburg其他文献

Elizabeth Anne Ramsburg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elizabeth Anne Ramsburg', 18)}}的其他基金

Efficacy of Light-Activated Anti-Microbial Fabrics against Human Pathogens
光激活抗菌织物对人类病原体的功效
  • 批准号:
    7907150
  • 财政年份:
    2011
  • 资助金额:
    $ 45.15万
  • 项目类别:
Vaccine Vector Comparison Study
疫苗载体比较研究
  • 批准号:
    7652093
  • 财政年份:
    2008
  • 资助金额:
    $ 45.15万
  • 项目类别:

相似海外基金

Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    9981001
  • 财政年份:
    2017
  • 资助金额:
    $ 45.15万
  • 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    9751102
  • 财政年份:
    2017
  • 资助金额:
    $ 45.15万
  • 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    9397073
  • 财政年份:
    2017
  • 资助金额:
    $ 45.15万
  • 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
  • 批准号:
    10223410
  • 财政年份:
    2017
  • 资助金额:
    $ 45.15万
  • 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-BETA (REBI
使用 SC IFN-β (REBI) 预防 MS 患者中和抗体形成
  • 批准号:
    7951676
  • 财政年份:
    2008
  • 资助金额:
    $ 45.15万
  • 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-β-AL
预防 SC IFN- 多发性硬化症患者中和抗体的形成
  • 批准号:
    7606036
  • 财政年份:
    2006
  • 资助金额:
    $ 45.15万
  • 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
  • 批准号:
    7375053
  • 财政年份:
    2005
  • 资助金额:
    $ 45.15万
  • 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
  • 批准号:
    7201220
  • 财政年份:
    2004
  • 资助金额:
    $ 45.15万
  • 项目类别:
Immunologic Mechanism of Inhibitor Antibody Formation in Hemophilia
血友病抑制剂抗体形成的免疫学机制
  • 批准号:
    6980810
  • 财政年份:
    2003
  • 资助金额:
    $ 45.15万
  • 项目类别:
INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE
血友病和冯·维勒布兰德病中的抑制剂抗体形成
  • 批准号:
    6419444
  • 财政年份:
    2000
  • 资助金额:
    $ 45.15万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了